Tailored rectal cancer treatment - A time for implementing contemporary prognostic factors?

Colorectal Disease

Volumn 15, Issue 11, 2013, Pages 1333-1342

  Wibe, A ^a,b   Law, W L ^c   Fazio, V ^d   Delaney, C P ^e,f  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

MRI; Prognostic factors; Rectal cancer; Tailored treatment

Indexed keywords

FLUOROURACIL;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DEFECATION DISORDER; DISTANT METASTASIS; DYSPAREUNIA; ERECTILE DYSFUNCTION; EXCISION; HIP FRACTURE; HUMAN; INCONTINENCE; KNOWLEDGE; LYMPH VESSEL METASTASIS; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERINEURAL INVASION; PRACTICE GUIDELINE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SECOND CANCER; TRANSRECTAL ULTRASONOGRAPHY; TUMOR INVASION; URINE INCONTINENCE; VAGINAL DRYNESS;

MRI; PROGNOSTIC FACTORS; RECTAL CANCER; TAILORED TREATMENT;

CHEMOTHERAPY, ADJUVANT; ENDOSONOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS;

EID: 84887184432     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12317     Document Type: Review

References (74)

1. National Institutes of Health. NIH Consensus Conference. JAMA 1990; 264: 1444-50.
2. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-15.
3. Glimelius B, Påhlman L, Cervantes A. ESMO Guidelines Working Group. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v82-6.
4. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. (Eds.) (2010) AJCC Cancer Staging Manual, 7th edtion. ISBN 978-0-387-88440-0.
5. Quirke P, Durdy P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumor spread and surgical excision. Lancet 1986; 2: 996-9.
6. Wibe A, Rendedal PR, Svensson E et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002; 89: 327-34.
7. Bernstein TE, Endreseth BH, Romundstad P, Wibe A, Norwegian Colorectal Cancer Group. Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 2009; 96: 1348-57.
8. Nagtegaal ID, Marijnen CA, Kranenbarg EK, van de Velde CJ, van Krieken JH. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002; 26: 350-7.
9. Wibe A. Magnetic resonance imaging for rectal cancer. Nat Clin Pract Oncol 2007; 4: 222-3. Epub 2007 Feb 27.
10. Daniels IR, Fisher SE, Heald RJ et al. Accurate staging, selective preoperative therapy and optimal surgery improves outcome in rectal cancer: a review of the recent evidence. Colorectal Dis 2007; 9: 290-301.
11. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006; 333: 779.
12. Beets-Tan RG, Beets GL. Rectal cancer: how accurate can imaging predict the T stage and the circumferential resection margin? Int J Colorectal Dis 2003; 18: 385-91. Epub 2003 Mar 7.
13. Taylor FG, Quirke P, Heald RJ et al. One millimetre is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer. Br J Surg 2011; 98: 872-9. doi: 10.1002/bjs.7458. Epub 2011 Apr 8.
14. Kim CK, Kim SH, Chun HK et al. Preoperative staging of rectal cancer: accuracy of 3-Tesla magnetic resonance imaging. Eur Radiol 2006; 16: 972-80. Epub 2006 Jan 17.
15. Videhult P, Smedh K, Lundin P et al. Magnetic resonance imaging for preoperative staging of rectal cancer in clinical practice: high accuracy in predicting circumferential margin with clinical benefit. Colorectal Dis 2007; 9: 412-9.
16. Kim YW, Kim NK, Min BS et al. A prospective comparison study for predicting circumferential resection margin between preoperative MRI and whole mount sections in mid-rectal cancer: significance of different scan planes. Eur J Surg Oncol 2008; 34: 648-54.
17. Gunderson LL, Callister M, Marschke R et al. Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status. Gastrointest Cancer Res 2008; 2: 25-33.
18. Willett CG, Badizadegan K, Ancukiewicz M et al. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 1999; 42: 167-73.
19. Kraemer M, Wiratkapun S, Seow-Choen F et al. Stratifying risk factors for follow-up: a comparison of recurrent and nonrecurrent colorectal cancer. Dis Colon Rectum 2001; 44: 815-21.
20. Günther K, Dworak O, Remke S et al. Prediction of distant metastases after curative surgery for rectal cancer. J Surg Res 2002; 103: 68-78.
21. Sprenger T, Rothe H, Jung K et al. Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol 2010; 8: 27.
22. Dresen RC, Peters EE, Rutten HJ et al. Local recurrence in rectal cancer can be predicted by histopathological factors. Eur J Surg Oncol 2009; 35: 1071-7. doi:10.1016/j.ejso.2009.03.007. Epub 2009 Apr 11.
23. Rades D, Kuhn H, Schultze J et al. Prognostic factors affecting locally recurrent rectal cancer and clinical significance of hemoglobin. Int J Radiat Oncol Biol Phys 2008; 70: 1087-93. Epub 2007 Sep 24.
24. Horn A, Dahl O, Morild I. Venous and neural invasion as predictors of recurrence in rectal adenocarcinoma. Dis Colon Rectum 1991; 34: 798-804.
25. Horn A, Dahl O, Morild I. The role of venous and neural invasion on survival in rectal adenocarcinoma. Dis Colon Rectum 1990; 33: 598-601.
26. Ceyhan GO, Liebl F, Maak M et al. The severity of neural invasion is a crucial prognostic factor in rectal cancer independent of neoadjuvant radiochemotherapy. Ann Surg 2010; 252: 797-804.
27. Augestad KM, Lindsetmo R-O, Stulberg J et al. International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams. World J Surg 2010; 34: 2689-700.
28. Wibe A, Eriksen MT, Syse A, Tretli S, Myrvold HE, Søreide O. Effect of hospital caseload on long-term outcome after standardization of rectal cancer surgery at a national level. Br J Surg 2005; 92: 217-24.
29. Peeters KC, Marijnen CA, Nagtegaal ID et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246: 693-701.
30. Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2009; (1): CD006041. doi: 10.1002/14651858.CD006041.pub2.
31. Gerard JP, Rostom Y, Gal J et al. Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments: lessons from a systematic review of recent randomized trials. Crit Rev Oncol Hematol 2012; 81: 21-8. Epub 2011 Mar 5.
32. van Gijn W, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575-82. doi: 10.1016/S1470-2045(11)70097-3. Epub 2011 May 17.
33. Bruheim K, Guren MG, Skovlund E et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76: 1005-11. Epub 2009 Jun 18.
34. Bruheim K, Guren MG, Dahl AA et al. Sexual function in males after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76: 1012-7.
35. Bruheim K, Tveit KM, Skovlund E et al. Sexual function in females after radiotherapy for rectal cancer. Acta Oncol 2010; 49: 826-32.
36. Birgisson H, Påhlman L, Gunnarsson U et al. Late adverse effects of radiation therapy for rectal cancer - a systematic overview. Acta Oncol 2007; 46: 504-16. Review.
37. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-82.
38. Enker WE, Merchant N, Cohen AM et al. Safety and efficacy of low anterior resection for rectal cancer: 681 consecutive cases from a specialty service. Ann Surg 1999; 230: 544-52; discussion 552-4.
39. Bjerkeset T, Edna TH. Rectal cancer: the influence of type of operation on local recurrence and survival. Eur J Surg 1996; 162: 643-8.
40. Wibe A, Møller B, Norstein J et al. A national strategic change in treatment policy for rectal cancer - implementation of total mesorectal excision (TME) as routine treatment in Norway. A national audit. Dis Colon Rectum 2002; 45: 857-66.
41. Wibe A, Eriksen MT, Syse A, Myrvold HE, Søreide O. Total mesorectal excision - what can be achieved by national audit? Colorectal Dis 2003; 5: 471-7.
42. Wibe A, Carlsen E, Dahl O et al. Nationwide quality assurance of rectal cancer treatment. Colorectal Dis 2006; 8: 224-9.
43. Pahlman L, Bohe M, Cedermark B. et al. The Swedish rectal cancer registry. Br J Surg 2007; 94: 1285-92.
44. Harling H, Bülow S, Kronborg O et al. Survival of rectal cancer patients in Denmark during 1994-99. Colorectal Dis 2004; 6: 153-7.
45. Bülow S, Harling H, Iversen LH et al. Improved survival after rectal cancer in Denmark. Colorectal Dis 2010; 12(7 Online): e37-42. Epub 2009 Jul 15.
46. Marijnen CA, Nagtegaal ID, Kapiteijn E et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003; 55: 1311-20.
47. Frasson M, Garcia-Granero E, Roda D et al. Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. Cancer 2011; 117: 3118-25.
48. Steel MC, Woods R, Mackay JM et al. Extent of mesorectal invasion is a prognostic indicator in T3 rectal carcinoma. ANZ J Surg 2002; 72: 483-7.
49. Harewood GC, Kumar KS, Clain JE et al. Clinical implications of quantification of mesorectal tumor invasion by endoscopic ultrasound: all T3 rectal cancers are not equal. J Gastroenterol Hepatol 2004; 19: 750-5.
50. Merkel S, Mansmann U, Siassi M et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001; 16: 298-304.
51. Miyoshi M, Ueno H, Hashiguchi Y et al. Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients. Ann Surg 2006; 243: 492-8.
52. Esclapez P, Garcia-Granero E, Flor B et al. Prognostic heterogeneity of endosonographic T3 rectal cancer. Dis Colon Rectum 2009; 52: 685-91.
53. Smith NJ, Barbachano Y, Norman AR, Swift RI, Abulafi AM, Brown G. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg 2008; 95: 229-36.
54. Merchant NB, Guillem JG, Paty PB et al. T3N0 Rectal Cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 1999; 3: 642-7.
55. Law WL, Ho JW, Chan R et al. Outcome of anterior resection for stage II rectal cancer without radiation: the role of adjuvant chemotherapy. Dis Colon Rectum 2005; 48: 218-26.
56. Lee JH, Jang HS, Kim JG et al. Lymphovascular invasion is a significant prognosticator in rectal cancer patients who receive preoperative chemoradiotherapy followed by total mesorectal excision. Ann Surg Oncol 2012; 19: 1213-21.
57. Du CZ, Xue WC, Cai Y et al. Lymphovascular invasion in rectal cancer following neoadjuvant radiotherapy: a retrospective cohort study. World J Gastroenterol 2009; 15: 3793-8.
58. Ptok H, Meyer F, Steinert R et al. No prognostic impact of isolated lymphovascular invasion after radical resection of rectal cancer-results of a multicenter observational study. Int J Colorectal Dis 2007; 22: 749-56.
59. Engelen SM, Beets GL, Beets-Tan RG. Role of preoperative local and distant staging in rectal cancer. Onkologie 2007; 30: 141-5. Epub 2007 Feb 16.
60. Torricelli P. Rectal cancer staging. Surg Oncol 2007; 16(Suppl 1): S49-50. Epub 2007 Nov 26.
61. Beets-Tan RG, Beets GL. Rectal cancer: review with emphasis on MR imaging. Radiology 2004; 232: 773-83.
62. Giusti S, Buccianti P, Castagna M et al. Preoperative rectal cancer staging with phased-array MR. Radiat Oncol 2012; 7: 29.
63. Bianchi PP, Ceriani C, Rottoli M et al. Endoscopic ultrasonography and magnetic resonance in preoperative staging of rectal cancer: comparison with histologic findings. J Gastrointest Surg 2005; 9: 1222-7; discussion 1227-8.
64. Halefoglu AM, Yildirim S, Avlanmis O et al. Endorectal ultrasonography versus phased-array magnetic resonance imaging for preoperative staging of rectal cancer. World J Gastroenterol 2008; 14: 3504-10.
65. Janjan NA, Crane C, Feig BW et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001; 24: 107-12.
66. Sanghera P, Wong DW, McConkey CC et al. Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol), 2008; 20: 176-83.
67. Park JH, Kim JH, Ahn SD et al. Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancer. Cancer Res Treat 2004; 36: 354-9.
68. Chari RS, Tyler DS, Anscher MS et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 1995; 221: 778-86.
69. Yu CS, Kim TW, Kim JH et al. Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 67: 1020-6.
70. Read TE, McNevin MS, Gross EK et al. Neoadjuvant therapy for adenocarcinoma of the rectum: tumour response and acute toxicity. Dis Colon Rectum 2001; 44: 513-22.
71. Habr-Gama A, Oliva Perez R. The strategy "wait and watch" in patients with a cancer of bottom stocking rectum with a complete clinical answer after neoadjuvant radiochemotherapy. J Chir (Paris) 2009; 146: 237-9.
72. Hiotis SH, Weber SM, Cohen AM et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 2002; 194: 131-5.
73. Nakagawa WT, Rossi BM, de O Ferreira F et al. Chemoradiation instead of surgery to treat mid and low rectal tumours: is it safe? Ann Surg Oncol, 2002; 9: 568-73.
74. Chang GJ, You YN, Park IJ et al. Pretreatment high-resolution rectal MRI and treatment response to neoadjuvant chemoradiation. Dis Colon Rectum 2012; 55: 371-7.